Young Breast Cancer Cohort Study

Breast Cancer Clinical Trial

— YBC  

Official title:

Prospective Cohort Study for Development of Personalized Treatment Strategy Based on Biologic Tumor Behavior and Clinical Characteristics in Young Breast Cancer (YBC) Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03131089
• Other study ID #: 2013-04-005
• Status: Recruiting
• Phase: N/A
• First received: April 16, 2017
• Last updated: April 26, 2017
• Start date: April 11, 2013
• Est. completion date: April 10, 2023

Study information

• Verified date: April 2017
• Source: Samsung Medical Center
• Contact: Yeon Hee Park, MD
• Phone: 82-2-3410-1780
• Email: yhparkhmo[@]skku.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is prospective cohort study to investigate and identify comprehensively the clinicopathological features and long-term outcome of young breast cancer (YBC).

We have enrolled Breast cancer patients under 40 year-old and collected their baseline characteristics including tumor character, familiar history and other background information. Moreover, we have collected breast cancer tissue/blood sample for analyzing genetic characteristics, if patient agree to genetic analysis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: April 10, 2023
• Est. primary completion date: February 17, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A to 40 Years

Eligibility

Inclusion Criteria:

1. Diagnosis with breast cancer

2. Age under 40 year-old or diagnosis with breast cancer at pregnancy or within 1year after delivery

3. Obtained informed consent form

Exclusion Criteria:

1) Cannot understand or disagree to informed consent form

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Locations

Country	Name	City	State
Korea, Republic of	Samsung Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival	Time to detect disease recurrence from surgery date	From date of surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months